Comparative Validation of Realtime Solar Wind Forecasting Using the UCSD Heliospheric Tomography Model

The University of California, San Diego 3D Heliospheric Tomography Model reconstructs the evolution of heliospheric structures, and can make forecasts of solar wind density and velocity up to 72 hours in the future. The latest model version, installed and running in realtime at the Community Coordinated Modeling Center(CCMC), analyzes scintillations of meter wavelength radio point sources recorded by the Solar-Terrestrial Environment Laboratory(STELab) together with realtime measurements of solar wind speed and density recorded by the Advanced Composition Explorer(ACE) Solar Wind Electron Proton Alpha Monitor(SWEPAM).The solution is reconstructed using tomographic techniques and a simple kinematic wind model. Since installation, the CCMC has been recording the model forecasts and comparing them with ACE measurements, and with forecasts made using other heliospheric models hosted by the CCMC. We report the preliminary results of this validation work and comparison with alternative models

Outburst of Comet 17P/Holmes Observed With The Solar Mass Ejection Imager

We present time-resolved photometric observations of Jupiter family comet 17P/Holmes during its dramatic outburst of 2007. The observations, from the orbiting Solar Mass Ejection Imager (SMEI), provide the most complete measure of the whole-coma brightness, free from the effects of instrumental saturation and with a time-resolution well-matched to the rapid brightening of the comet. The lightcurve is divided into two distinct parts. A rapid rise between the first SMEI observation on UT 2007 October 24 06h 37m (mid-integration) and UT 2007 October 25, is followed by a slow decline until the last SMEI observation on UT 2008 April 6 22h 16m (mid-integration). We find that the rate of change of the brightness is reasonably well-described by a Gaussian function having a central time of UT 2007 October 24.54+/-0.01 and a full-width-at-half-maximum 0.44+/-0.02 days. The maximum rate of brightening occurs some 1.2 days after the onset of activity. At the peak the scattering cross-section grows at 1070+/-40 km^2/s while the (model-dependent) mass loss rates inferred from the lightcurve reach a maximum at 3+/-10^5 kg/s. The integrated mass in the coma lies in the range (2 to 90)x10^10 kg, corresponding to 0.2% to 10% of the nucleus mass, while the kinetic energy of the ejecta is (0.6 to 30) MTonnes TNT. The particulate coma mass could be contained within a shell on the nucleus of thickness ~1.5 to 60 m. This is comparable to the distance traveled by conducted heat in the century since the previous outburst of 17P/Holmes. This coincidence is consistent with, but does not prove, the idea that the outburst was triggered by the action of conducted heat, possibly through the crystallization of buried amorphous ice.Comment: 27 pages, 8 figures; http://www2.ess.ucla.edu/~jingli/Holmes_SMEI/17P_Holmes.htm

The Lantern Vol. 19, No. 3, Summer 1951

• Up in the Air • On Considering a Wallet\u27s State of Emptiness • You Came from Heaven • If At First • Memory of Winter Mornings • The Night We All Got Drunk • Composer Thomas Waller Enters into Heaven • Elegy in Times Square • To Spring • The Cliff of Morality • An Evening Drive • Liberty • Begone • Limerick with a Leer • Two Allusive Limerickshttps://digitalcommons.ursinus.edu/lantern/1054/thumbnail.jp

The NASA/IPAC Infrared Science Archive (IRSA): The Demo

This paper describes the services available at the NASA/IPAC Infrared Science Archive (IRSA). Currently there are nearly 250,000 data requests a month, taking advantage of IRSA's data repository which includes 660 million sources (60 catalogs), 10 million images (22 image sets; 10.4 TB) and over 30,000 spectra (7 spectroscopic datasets). These data are the science products of: The Two Micron All Sky Survey (2MASS), The Infrared Astronomical Satellite (IRAS), The Midcourse Space Experiment (MSX), The Submillimeter Wave Astronomy Satellite (SWAS), The Infrared Space Observatory (ISO), The Infrared Telescope in Space (IRTS), The Spitzer First Look Survey (FLS), Spitzer Legacy & Ancillary data, Spitzer Reserved Observations (ROC) and the Spitzer Space Telescope data. IRSA is also seamlessly interoperable with ten remote archives and services: GOODS, ISO, MAST, VizieR, DSS, NVSS, FIRST, HEASARC, NED and JPL, which help expand the available dataset wavelength range from X-ray to radio. The majority of IRSA's image collections are Simple Image Access (SIA) compliant and are available through the Virtual Observatory (VO) data mining tools. The IRSA demo includes IRSA's ¯ve main services: inventory service RADAR, catalog query service Gator, data fusion service OASIS, general search service for complex data collections Atlas, and IRSA's 2MASS Image data access services. IRSA's website is http://irsa.ipac.caltech.edu

Spiroindolines Identify the Vesicular Acetylcholine Transporter as a Novel Target for Insecticide Action

The efficacy of all major insecticide classes continues to be eroded by the development of resistance mediated, in part, by selection of alleles encoding insecticide insensitive target proteins. The discovery of new insecticide classes acting at novel protein binding sites is therefore important for the continued protection of the food supply from insect predators, and of human and animal health from insect borne disease. Here we describe a novel class of insecticides (Spiroindolines) encompassing molecules that combine excellent activity against major agricultural pest species with low mammalian toxicity. We confidently assign the vesicular acetylcholine transporter as the molecular target of Spiroindolines through the combination of molecular genetics in model organisms with a pharmacological approach in insect tissues. The vesicular acetylcholine transporter can now be added to the list of validated insecticide targets in the acetylcholine signalling pathway and we anticipate that this will lead to the discovery of novel molecules useful in sustaining agriculture. In addition to their potential as insecticides and nematocides, Spiroindolines represent the only other class of chemical ligands for the vesicular acetylcholine transporter since those based on the discovery of vesamicol over 40 years ago, and as such, have potential to provide more selective tools for PET imaging in the diagnosis of neurodegenerative disease. They also provide novel biochemical tools for studies of the function of this protein family

Depression prevalence using the HADS-D compared to SCID major depression classification:An individual participant data meta-analysis

Objectives: Validated diagnostic interviews are required to classify depression status and estimate prevalence of disorder, but screening tools are often used instead. We used individual participant data meta-analysis to compare prevalence based on standard Hospital Anxiety and Depression Scale – depression subscale (HADS-D) cutoffs of ≥8 and ≥11 versus Structured Clinical Interview for DSM (SCID) major depression and determined if an alternative HADS-D cutoff could more accurately estimate prevalence. Methods: We searched Medline, Medline In-Process & Other Non-Indexed Citations via Ovid, PsycINFO, and Web of Science (inception-July 11, 2016) for studies comparing HADS-D scores to SCID major depression status. Pooled prevalence and pooled differences in prevalence for HADS-D cutoffs versus SCID major depression were estimated. Results: 6005 participants (689 SCID major depression cases) from 41 primary studies were included. Pooled prevalence was 24.5% (95% Confidence Interval (CI): 20.5%, 29.0%) for HADS-D ≥8, 10.7% (95% CI: 8.3%, 13.8%) for HADS-D ≥11, and 11.6% (95% CI: 9.2%, 14.6%) for SCID major depression. HADS-D ≥11 was closest to SCID major depression prevalence, but the 95% prediction interval for the difference that could be expected for HADS-D ≥11 versus SCID in a new study was −21.1% to 19.5%. Conclusions: HADS-D ≥8 substantially overestimates depression prevalence. Of all possible cutoff thresholds, HADS-D ≥11 was closest to the SCID, but there was substantial heterogeneity in the difference between HADS-D ≥11 and SCID-based estimates. HADS-D should not be used as a substitute for a validated diagnostic interview.This study was funded by the Canadian Institutes of Health Research (CIHR, KRS-144045 & PCG 155468). Ms. Neupane was supported by a G.R. Caverhill Fellowship from the Faculty of Medicine, McGill University. Drs. Levis and Wu were supported by Fonds de recherche du Québec - Santé (FRQS) Postdoctoral Training Fellowships. Mr. Bhandari was supported by a studentship from the Research Institute of the McGill University Health Centre. Ms. Rice was supported by a Vanier Canada Graduate Scholarship. Dr. Patten was supported by a Senior Health Scholar award from Alberta Innovates, Health Solutions. The primary study by Scott et al. was supported by the Cumming School of Medicine and Alberta Health Services through the Calgary Health Trust, and funding from the Hotchkiss Brain Institute. The primary study by Amoozegar et al. was supported by the Alberta Health Services, the University of Calgary Faculty of Medicine, and the Hotchkiss Brain Institute. The primary study by Cheung et al. was supported by the Waikato Clinical School, University of Auckland, the Waikato Medical Research Foundation and the Waikato Respiratory Research Fund. The primary study by Cukor et al. was supported in part by a Promoting Psychological Research and Training on Health-Disparities Issues at Ethnic Minority Serving Institutions Grants (ProDIGs) awarded to Dr. Cukor from the American Psychological Association. The primary study by De Souza et al. was supported by Birmingham and Solihull Mental Health Foundation Trust. The primary study by Honarmand et al. was supported by a grant from the Multiple Sclerosis Society of Canada. The primary study by Fischer et al. was supported as part of the RECODEHF study by the German Federal Ministry of Education and Research (01GY1150). The primary study by Gagnon et al. was supported by the Drummond Foundation and the Department of Psychiatry, University Health Network. The primary study by Akechi et al. was supported in part by a Grant-in-Aid for Cancer Research (11−2) from the Japanese Ministry of Health, Labour and Welfare and a Grant-in-Aid for Young Scientists (B) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The primary study by Kugaya et al. was supported in part by a Grant-in-Aid for Cancer Research (9–31) and the Second-Term Comprehensive 10-year Strategy for Cancer Control from the Japanese Ministry of Health, Labour and Welfare. The primary study Ryan et al. was supported by the Irish Cancer Society (Grant CRP08GAL). The primary study by Keller et al. was supported by the Medical Faculty of the University of Heidelberg (grant no. 175/2000). The primary study by Love et al. (2004) was supported by the Kathleen Cuningham Foundation (National Breast Cancer Foundation), the Cancer Council of Victoria and the National Health and Medical Research Council. The primary study by Love et al. (2002) was supported by a grant from the Bethlehem Griffiths Research Foundation. The primary study by Löwe et al. was supported by the medical faculty of the University of Heidelberg, Germany (Project 121/2000). The primary study by Navines et al. was supported in part by the Spanish grants from the Fondo de Investigación en Salud, Instituto de Salud Carlos III (EO PI08/90869 and PSIGEN-VHC Study: FIS-E08/00268) and the support of FEDER (one way to make Europe). The primary study by O'Rourke et al. was supported by the Scottish Home and Health Department, Stroke Association, and Medical Research Council. The primary study by Sanchez-Gistau et al. was supported by a grant from the Ministry of Health of Spain (PI040418) and in part by Catalonia Government, DURSI 2009SGR1119. The primary study by Gould et al. was supported by the Transport Accident Commission Grant. The primary study by Rooney et al. was supported by the NHS Lothian Neuro-Oncology Endowment Fund. The primary study by Schwarzbold et al. was supported by PRONEX Program (NENASC Project) and PPSUS Program of Fundaçao de Amparo a esquisa e Inovacao do Estado de Santa Catarina (FAPESC) and the National Science and Technology Institute for Translational Medicine (INCT-TM). The primary study by Simard et al. was supported by IDEA grants from the Canadian Prostate Cancer Research Initiative and the Canadian Breast Cancer Research Alliance, as well as a studentship from the Canadian Institutes of Health Research. The primary study by Singer et al. (2009) was supported by a grant from the German Federal Ministry for Education and Research (no. 01ZZ0106). The primary study by Singer et al. (2008) was supported by grants from the German Federal Ministry for Education and Research (# 7DZAIQTX) and of the University of Leipzig (# formel. 1–57). The primary study by Meyer et al. was supported by the Federal Ministry of Education and Research (BMBF). The primary study by Stone et al. was supported by the Medical Research Council, UK and Chest Heart and Stroke, Scotland. The primary study by Turner et al. was supported by a bequest from Jennie Thomas through Hunter Medical Research Institute. The primary study by Walterfang et al. was supported by Melbourne Health. Drs. Benedetti and Thombs were supported by FRQS researcher salary awards. No other authors reported funding for primary studies or for their work on this study. No funder had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication